POLUS GLOBAL FUND

(Company No.: C110931 C1/GBL)

Date: 01 February 2019

Bombay Stock Exchange Limited (BSE) P J Towers, Dalal Street, Mumbai-400 001

By Email: corp.relations@bseindia.com

Sub: Intimation/Disclosures under SEBI (SAST) Regulations, 2011 – Bliss GVS Pharma Limited

Dear Sir/Madam,

Please find enclosed a declaration in the prescribed format for the acquisition of Equity of Bliss GVS Pharma Limited in due compliance with regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

We kindly request to update your records accordingly.

Your Faithfully,

For and on the behalf of Polus Global Fund

Vidyotma LOTUN Director

Encs.

POLUS GLOBAL FUND

(Company No.: C110931 C1/GBL)

Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	BLISS GVS PHARMA LIMITED			
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	POLUS GLOBAL FUND			
Whether the acquirer belongs to Promoter/Promoter group	NON-PROMOTER			
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited (BSE) and National Stock Exchange of India Ltd (NSE)			
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)	
Before the acquisition under consideration, holding of acquirer along with PACs of:				
a) Shares carrying voting rights	950,000	0.9210	0.9210	
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0	0	
c) Voting rights (VR) otherwise than by equity shares d) Warrants/convertible securities/any other instrument	0	0	0	
that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0	0	
e) Total (a+b+c+d)	950,000	0.9210	0.9210	
Details of acquisition				
a) Shares carrying voting rights acquired	8,300,000	8.0468	8.0468	
b) VRs acquired otherwise than by equity sharesc) Warrants/convertible securities/any other instrument	0	0	0	
that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each	0	0	0	

POLUS GLOBAL FUND

(Company No.: C110931 C1/GBL)

 category) acquired d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) e) Total (a+b+c+/-d) 	0	0	0
	8,300,000	8.0468	8.0468
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rightsb) VRs otherwise than by equity shares	9,250,000	8.9678 0	8.9678 0
 c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition 	0	0	0
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0	0
e) Total (a+b+c+d)	9,250,000	8.9678	8.9678
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	OPEN MARKET (IN NSE AND BSE)		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	N/A		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	01 FEBRUARY 2019		
Equity share capital / total voting capital of the TC before the said acquisition	103,146,672		
Equity share capital/ total voting capital of the TC after the said acquisition		103,146.0	672
Total diluted share/voting capital of the TC after the said acquisition	103,146,672		

For and on behalf of POLUS GLOBAL FUND



Place: Maurifius

Date: 01 February 2019

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.